ARK Invest CEO Cathie Wood just trimmed $2.29 million worth of Roku Inc. (ROKU) stock, at a point when it has been anything but quiet. The move came Jan. 7, with Roku stock on an excellent run, delivering a 10% gain in the past month, as the broader market struggles. For perspective, Roku was ...
If theres one thing Ive learned in over 30 years of investing, including 28 on Wall Streets sell side, its that markets arent a fan of uncertainty. The stock market performs best when a trend is established, and everyone has a clear understanding of possible outcomes; it struggles ahead of ...
Die Deutsche Telekom überzeugt im Robustheits-Check von TraderFox mit 15 von 15 möglichen Punkten. Der defensive Charakter des Geschäftsmodells mit Fokus auf den Telekommunikationsbereich und die lukrative...
PARIS/LONDON/ZÜRICH (dpa-AFX) - Europas Aktienmärkte haben am Donnerstag uneinheitlich geschlossen. Der EuroStoxx 50 gab um 0,32 Prozent auf 5.904,32 Punkte nach. Zum Wochenauftakt war der Leitindex für die Eurozone auf ein Rekordhoch gestiegen, ans...
Nach den Kursverlusten im November notieren die Börsen nahe ihren Höchstständen. Unabhängig davon, wie sich die Lage entwickelt, ist es wichtig, das Portfolio kritisch zu hinterfragen.
First Horizon (FHN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Deluxe (DLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
First Hawaiian (FHB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cullen/Frost (CFR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CNX Resources (CNX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Customers Bancorp (CUBI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dolby Laboratories (DLB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Boyd (BYD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CBOE (CBOE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BOK Financial (BOKF) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Brown & Brown (BRO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Hubbell (HUBB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bank of Hawaii (BOH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wells Fargo (WFC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Nextracker (NXT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
By David Bautz, PhDNASDAQ:FBLGREAD THE FULL FBLG RESEARCH REPORTBusiness UpdateApproval from HREC for Phase 1/2 Diabetic Foot Ulcer TrialIn November 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced that it has received both public and private Human Research Ethics Committee (HREC) approvals in Australia for the planned Phase 1/2 clinical trial of CYWC628 for the treatment of refractory Diabetic Foot Ulcers (DFU). The approval allows for enrollment of 120 patients across 10 clinical sites...
Novo Nordisk’s Wegovy weight loss pill hit U.S. pharmacies this week. Here’s how it works, who qualifies, how to take it, side effects, cost, and why it matters now.
Constellation Brands executives said on Thursday beer sales could remain volatile and under pressure as economic uncertainty and high unemployment among Hispanic consumers, its core customer base, continue to weigh on spending.
Frankfurt (www.aktiencheck.de) - NVIDIA-Aktienanalyse von XTB:Die Experten von XTB nehmen die Aktie von NVIDIA Corp. (ISIN: US67066G1040, WKN: 918422, Ticker-Symbol: NVD, NASDAQ-Symbol: NVDA) in einer aktuellen Marktanalyse unter die Lupe.Börse Aktuell richte sich der Blick vieler Investoren auf NVIDIA. [mehr]
CSP exits FY25 with an 800-bps gross margin jump as high-margin services scale and AZT PROTECT gains multi-site traction via Rockwell channels, setting up stronger FY26 visibility.
Der DAX hat den vierten Tag in Folge neue Rekorde markiert und stieg am Morgen auf ein neues Allzeithoch von 25.218 Punkten. „Investoren positionieren sich auf eine mögliche Trendwende in der Konjunktur“, so Marktexperte Andreas Lipkow im Gespräch mit Dietmar Deffner.
FRANKFURT (dpa-AFX) - Nach dem Sprung über 25.000 Punkte im Dax am Vortag und einem fortgesetzten Rekordlauf an diesem Donnerstag bis über 25.200 Punkte haben es die Anleger etwas langsamer angehen lassen. Der deutsche Leitindex schloss mit plus 0,0...
Bad Marienberg (www.aktiencheck.de)???????? Meta Platforms im KI-Synergie-Modus: Cantor Fitzgerald erhöht Kursziel 750 USD und bleibt bei Rating "overweight"Es ist ein seltenes Börsenphänomen: Eine Technologie startet als faszinierender Hype, verschlingt Milliarden an Investitionen - und plötzlich, fast über Nacht, wird sie zu einem messbaren, planbaren Renditehebel. [mehr]
Im US-Musterdepot von TraderFox setzen wir seit dem 05.06.2025 zu einem Kurs von 45,47 USD auf Karman. Der Buchgewinn: 120 %! Karman hat sich als ein führender "Tier-1"-Zulieferer in den Bereichen Luft-...
Scotts (SMG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Central Garden (CENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Knot Offshore (KNOP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Morgan Stanley (MS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Edison International (EIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
First Western (MYFW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Synaptics (SYNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Nvidia (NASDAQ:NVDA), a GPU and AI solutions leader, closed Thursdays session at $185, down 2.17%. Nvidia IPOd in 1999 and has grown an astounding 450,934% since going public. Trading volume reached 163.5 million shares, coming in nearly 12% below versus its three-month average
Ford Motor Company (NYSE:F), a maker of automobiles and commercial vehicles, closed Thursdays session at $14.40, up 4.80%. Ford Motor Company IPOd in 1972 and has grown 563% since going public. Trading volume reached 145.2 million shares, about 71% above its three-month average
An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle strength, mobility, and survival.
Does NRDSs affiliate-driven model, user growth and strategic acquisition tilt the long-term digital finance battle in its favor compared with TREE? Let us find out.